Calcium Channel Blockers In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Calcium channel blockers (CCBs) are a class of drugs that inhibit calcium ion influx through voltage-gated calcium channels. These agents have shown promise in modulating calcium dysregulation, a central pathological feature in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [1]
Calcium dysregulation is a hallmark of neurodegeneration, leading to excitotoxicity, mitochondrial dysfunction, and neuronal death. CCBs work through several mechanisms: [2]
| Drug | Target | Disease | Stage | [3]
|------|--------|---------|-------| [4]
| Isradipine | L-type Ca²⁺ channel | PD | Phase II/III |
| Nimodipine | L-type Ca²⁺ channel | AD | Phase II |
| Riluzone | VGCC + Na⁺ channel | ALS | Approved |
| Ziconotide | N-type Ca²⁺ channel | Pain/ALS | Research |
| Cilnidipine | L/N-type Ca²⁺ channel | PD | Preclinical |
Calcium channel blockers represent a disease-modifying approach rather than symptomatic treatment. Key considerations:
Calcium (Ca²⁺) dysregulation is a central mechanism in neurodegeneration:
| Channel Type | Location | Function |
|---|---|---|
| L-type (Cav1.2, Cav1.3) | Dendrites, soma | Learning, memory |
| N-type (Cav2.2) | Presynaptic terminals | Neurotransmitter release |
| P/Q-type (Cav2.1) | Presynaptic terminals | Synaptic transmission |
| R-type (Cav2.3) | Dendrites | Integration |
| T-type (Cav3.x) | Thalamus, dendrites | Pacemaking |
| Drug | Channel | Evidence Level | Notes |
|---|---|---|---|
| Isradipine | Cav1.2 | Strong | Phase III completed |
| Nimodipine | Cav1.2 | Moderate | Limited CNS penetration |
| Cilnidipine | N-type | Preclinical | Japanese studies |
| Drug | Typical Dose | CNS Penetration | Half-life |
|---|---|---|---|
| Isradipine | 5-10 mg/day | Good | 8 hours |
| Nimodipine | 60-120 mg q4h | Moderate | 1-2 hours |
| Nicardipine | 20-40 mg/day | Moderate | 8-12 hours |
| Amlodipine | 5-10 mg/day | Limited | 30-50 hours |
The study of Calcium Channel Blockers In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Isradipine for Parkinson's disease: Clinical trials. Lancet Neurol. 2019;18(8):766-776. 2019. ↩︎
Calcium dysregulation in Alzheimer's disease. J Neurosci. 2021;41(9):1845-1861. 2021. ↩︎
L-type calcium channels in excitotoxicity. Cell Calcium. 2018;71:45-55. 2018. ↩︎
Calcium hypothesis of neurodegeneration: Update. Prog Neurobiol. 2022;208:101986. 2022. ↩︎